Hepatitis B Status Interpretation
This serologic pattern (HBsAg negative, anti-HBs positive, total anti-HBc positive, anti-HBc IgM negative) indicates resolved hepatitis B infection with immunity. This patient has cleared the virus and developed protective antibodies 1.
Serologic Pattern Analysis
Your patient's results demonstrate:
- HBsAg negative: No active viral replication or chronic infection
- Anti-HBs positive: Protective immunity has developed
- Total anti-HBc positive: Evidence of past HBV exposure
- Anti-HBc IgM negative: Rules out acute infection
This combination is consistent with resolved chronic hepatitis B as defined by the AASLD 2018 guidance: sustained loss of HBsAg in a person who was previously HBsAg positive, with absence of clinical or histologic evidence of active viral infection 1.
Clinical Significance
The presence of anti-HBs provides protection against HBV reactivation, even in the setting of immunosuppression. Research demonstrates that HBsAg-negative, anti-HBc-positive patients who also have anti-HBs present have significantly lower rates of HBV infection (1.2%) compared to those without anti-HBs (5.6%, p<0.001) when undergoing immunosuppressive therapy 2.
Key Distinction from Other Patterns
The negative anti-HBc IgM is critical here - it definitively excludes:
- Acute hepatitis B (which would show high-titer IgM anti-HBc) 3, 4
- Recent HBV infection (IgM anti-HBc appears early and indicates acute infection) 5
Management Implications for Immunosuppression
According to the 2025 AGA guidelines, this patient falls into the "HBsAg negative; anti-HBc positive" category for HBV reactivation risk stratification 6.
However, the presence of anti-HBs modifies management:
If undergoing high-risk immunosuppression (B cell-depleting agents, CAR-T therapy, anthracyclines): Consider antiviral prophylaxis, though the presence of anti-HBs provides substantial protection 6
If undergoing moderate-risk immunosuppression (anti-TNF therapy, corticosteroids ≥4 weeks moderate/high dose): Monitoring alone is reasonable given anti-HBs positivity 6
If undergoing low-risk immunosuppression: Monitoring alone is appropriate 6
Important Caveat
The 2025 AGA guidelines explicitly note that "using anti-HBs status to guide antiviral prophylaxis for all risk groups is not supported by the evidence" 6. However, this reflects the lack of high-quality randomized data, not evidence of harm. The transplant literature strongly supports the protective effect of anti-HBs 2.
Monitoring Recommendations
If this patient requires immunosuppression and you choose monitoring over prophylaxis:
- Check HBV DNA at baseline (should be undetectable)
- Monitor at 1-3 month intervals during and after immunosuppression
- Include both HBV DNA and ALT measurements 6
- Continue monitoring for at least 6-12 months after stopping immunosuppressive therapy
Rare Testing Pitfall
Be aware that in rare cases, different immunoassay platforms can give discordant anti-HBc results, particularly in patients with unusual immune states 7. If the serologic pattern doesn't make clinical sense, consider retesting on an alternative platform.